Knight Therapeutics - President and CEO, Samira Sakhia.
President and CEO, Samira Sakhia.
Source: Knight Therapeutics.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Knight (GUD) has assumed full commercial activities for oral AKYNZEO in Canada
  • AKYNZEO (netupitant/palonosetron capsules) is approved in Canada to prevent nausea and vomiting from chemotherapy and other emetogenic cancer therapies
  • According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021
  • Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or licensing products for Canada and Latin America
  • Knight Therapeutics (GUD) is unchanged, trading at $5.40 per share

Knight (GUD) has assumed full commercial activities for oral AKYNZEO in Canada.

AKYNZEO (netupitant/palonosetron capsules) is approved in Canada to prevent nausea and vomiting from chemotherapy and other emetogenic cancer therapies.

A single dose of AKYNZEO with dexamethasone prior to chemotherapy has been shown to prevent nausea and vomiting for up to five days.

Knight and Helsinn Healthcare entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV in Canada in May 2022.

According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.

“We are excited to take over the Canadian commercialization of AKYNZEO, an innovative once-per-cycle fixed-dose, dual combination antiemetic,” stated Samira Sakhia, Knight’s President and CEO. “AKYNZEO builds upon Knight’s growing Canadian oncology portfolio, increasing our presence in this important therapeutic area.”

Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or licensing products for Canada and Latin America. 

Knight Therapeutics (GUD) is unchanged, trading at $5.40 per share as of 1:44 pm ET.


More From The Market Herald

" @ the Bell: Growth-sensitive stocks fluctuate on mega jobs report

Canada’s main stock index ended on the higher side of flat on Friday trading as strength in the energy and technology sectors was weighed against

" Aimia (TSX:AIM) sells $7.36M in shares to Mithaq Capital

Aimia (AIM) has sold approximately $7.36 million of its common shares to investor company Mithaq Capital SPC.

" Terra Firma Capital (TSXV:TII) appoints new board member

Terra Firma Capital (TII) appoints Mike Kirchmair as a member of the corporation’s board of directors.
Capital Power Corporation - The Whitla Wind Facility

" Capital Power (TSX:CPX) looks forward to protecting the environment

Capital Power Corporation (CPX) enters a 23-year clean electricity supply agreement with Public Services and Procurement Canada to protect the environment.